Glenmark Pharmaceuticals Ltd announced on Monday, December 16, that its U.S. subsidiary has launched Lacosamide Oral Solution, 10 mg/mL, an oral medication for managing seizures. The product is bioequivalent and therapeutically comparable to Vimpat Oral Solution, 10 mg/mL, developed by UCB, Inc. It is primarily used to treat partial-onset seizures as well as primary generalized tonic-clonic seizures.
According to IQVIA’s market data for the 12 months ending October 2024, the Vimpat Oral Solution 10 mg/mL segment recorded annual sales of approximately $57 million.
Marc Kikuchi, President and Business Head of Glenmark North America, expressed enthusiasm about the launch, highlighting the company’s dedication to delivering affordable and high-quality treatment alternatives for patients.
Separately, glenmark pharma recently shared updates from the Phase 1 clinical trial of its Trispecific TREAT Antibody, ISB 2001. Initial results demonstrated promising outcomes in patients with heavily pretreated Multiple Myeloma. Among 20 patients treated as of October 1, 2024, an overall response rate (ORR) of 75% was observed across all dosage levels, ranging from 0.005 to 1.2 mg/kg. The data included a stringent complete remission (sCR) and complete remission (CR) rate of 20%.
These findings suggest that ISB 2001 could potentially outperform some of the currently approved bispecific options in the market, according to Glenmark.
On the same day, Glenmark Pharma’s shares traded 1.23% higher at ₹1,536.80 per share. Year-to-date, the stock has shown a remarkable 79.61% increase.
